Overactive Bladder Therapeutics Market by Product and Geography - Forecast and Analysis 2020-2024

The overactive bladder therapeutics market size has the potential to grow by USD 311.17 million during 2020-2024, and the market's growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by product (anticholinergics, beta-3 adrenergic agonists, and other OAB therapeutics) and geography (North America, Europe, Asia, and ROW). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including AbbVie Inc., Astellas Pharma Inc., Endo International Plc, Johnson & Johnson, Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Overactive Bladder Therapeutics Market

Request a FREE sample now!

Market Competitive Analysis

The market is fragmented. AbbVie Inc., Astellas Pharma Inc., and Endo International Plc are some of the major market participants. Although the advent of combination therapy will offer immense growth opportunities, the side effects associated with OAB will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this overactive bladder therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market's competitive landscape and offers information on the products offered by various companies. Moreover, this overactive bladder therapeutics market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

• AbbVie Inc.
• Astellas Pharma Inc.
• Endo International Plc
• Johnson & Johnson
• Merck & Co. Inc.
• Mylan NV
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Overactive Bladder Therapeutics Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

North America was the largest overactive bladder therapeutics market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The rising incidence of OAB in the US will significantly drive overactive bladder therapeutics market growth in this region over the forecast period.

41% of the market's growth will originate from North America during the forecast period. The US is the key market for overactive bladder therapeutics in North America. Market growth in this region will be faster than the growth of the market in other regions.

Overactive Bladder Therapeutics Market: Segmentation by Product

Request for a FREE sample and Get more information on the market contribution of various segments

The increasing availability of branded drugs, which provides patients with a wide range of therapeutics to choose from is driving the anticholinergics market segment. Therefore, the overactive bladder therapeutics market share growth by the anticholinergics segment will be significant during the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the overactive bladder therapeutics market size.

Overactive Bladder Therapeutics Market: Key Drivers and Trends

The administration of anticholinergics has remained the mainstay treatment. However, the rising R&D in drug development has recently given rise to beta-3 adrenergic agonists. Despite the therapeutic efficacy of these drugs, which are administered as monotherapy, they are associated with adverse effects. Therefore, there is a significant unmet need for effective therapeutics for the treatment of OAB. As a result, vendors are increasingly spending on R&D to launch improved drugs. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. It also involves a shorter duration of treatment, improving patient compliance. As a result, the demand for combination therapy drugs is increasing. The advent of combination therapy is expected to significantly contribute to overactive bladder therapeutics market growth during 2020-2024.

The side-effects of the currently available drugs are increasing the demand for alternative therapeutics with fewer adverse effects and higher efficacy. As a result, vendors are focusing on developing novel therapies. Urovant Sciences is already conducting Phase I trial for its novel gene therapy, URO-902, to treat patients who have failed to respond to the available pharmacological therapeutics. The Phase II trial is in the pipeline, and the company has received an exclusive license to develop, manufacture, and commercialize the drug. It is expected to obtain a patent as well by 2038. This will induce other vendors to follow suit and invest in R&D to introduce improved gene therapies. With upcoming overactive bladder therapeutics market trends such as the advent of gene therapy, the market is expected to record a CAGR of almost 2%.

Request for a FREE sample

Overactive Bladder Therapeutics Market: Key Highlights of the Report for 2020-2024

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will drive overactive bladder therapeutics market growth during the next five years
• Precise estimation of the overactive bladder therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the overactive bladder therapeutics industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of overactive bladder therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch